Heparin-induced Thrombocytopenia (HIT II) in Liver Transplant Recipients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

39 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-01-31

Study Completion Date

2011-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In a prospective observational study the incidence of Heparin-induced Thrombocytopenia (HIT) Type 2 after orthotopic liver transplantation, associated factors, and hemostaseological findings in thrombocytes and anti-body patterns is going to be investigated.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators examined the frequency of anti-PF4/heparin antibodies (IgG/M/A; EIA) and their functional activity (HIPA) in 38 whole organ deceased donor liver transplant recipients. Additionally, demographic, clinical, donor- and recipient-specific parameters and laboratory findings (ALAT, ASAT, cholinesterase) were investigated.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heparin-induced Thrombocytopenia Liver Transplantation

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

liver transplantation thrombocytes heparin-induced thrombocytopenia multivariate analysis of associated factors of HIT 2 after OLT laboratory investigations of HIT-antibodies

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

orthotopic Liver Transplantation

consecutive inclusion of all recipients

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* all consecutive liver transplant recipients between 01/2010 and 08/2011 who
* were transplanted at our center after allocation of a liver graft via Eurotransplant

Exclusion Criteria

* patient's refusal to participate in prospective observation

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Volker Assfalg, MD

Role: PRINCIPAL_INVESTIGATOR

Klinikum rechts der Isar, Dept. of Surgery

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Klinikum rechts der Isar der TU München

Munich, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HITafterOLT

Identifier Type: OTHER

Identifier Source: secondary_id

TransplanTUM-1

Identifier Type: -

Identifier Source: org_study_id